These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30341983)

  • 1. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Di Stefano J; Knepley C; Limaye S; Mamtani R; Wisnivesky J; Damjanov N; Langer CJ; Cohen RB; Sigel K
    Cancer; 2019 Feb; 125(3):406-415. PubMed ID: 30341983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
    Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
    Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
    Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
    Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
    Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
    JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
    Xiang M; Colevas AD; Holsinger FC; Le QX; Beadle BM
    J Natl Compr Canc Netw; 2019 Sep; 17(9):1065-1073. PubMed ID: 31487677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
    Tang WH; Sun W; Long GX
    Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    Gebre-Medhin M; Brun E; Engström P; Haugen Cange H; Hammarstedt-Nordenvall L; Reizenstein J; Nyman J; Abel E; Friesland S; Sjödin H; Carlsson H; Söderkvist K; Thomasson M; Zackrisson B; Nilsson P
    J Clin Oncol; 2021 Jan; 39(1):38-47. PubMed ID: 33052757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
    Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
    Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
    Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
    Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
    Oppelt P; Ley J; Daly M; Rich J; Paniello R; Jackson RS; Pipkorn P; Liu J; Gay H; Palka K; Neupane P; Powell S; Spanos WC; Gitau M; Zevallos J; Thorstad W; Adkins D
    Med Oncol; 2021 Mar; 38(4):35. PubMed ID: 33683482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
    Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
    Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
    Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
    Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
    Saraswathula A; Chen MM; Colevas AD; Divi V
    JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1160-1167. PubMed ID: 31621810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.
    Ley J; Mehan P; Wildes TM; Thorstad W; Gay HA; Michel L; Nussenbaum B; Trinkaus K; Adkins D
    Oncology; 2013; 85(5):290-6. PubMed ID: 24217231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
    Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
    Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.
    Korpics MC; Turchan WT; Koshy M; Spiotto MT
    Head Neck; 2022 Jul; 44(7):1528-1544. PubMed ID: 35393753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.